Objective. We propose 2 Medical Dictionary for Regulatory Activities-enabled pharmacovigilance algorithms, MetaLAB and MetaNurse, powered by a per-year meta-analysis technique and improved subject sampling strategy. Matrials and methods. This study developed 2 novel algorithms, MetaLAB for laboratory abnormalities and MetaNurse for standard nursing statements, as significantly improved versions of our previous electronic health record (EHR)-based pharmacovigilance method, called CLEAR. Adverse drug reaction (ADR) signals from 117 laboratory abnormalities and 1357 standard nursing statements for all precautionary drugs (n ¼ 101) were comprehensively detected and validated against SIDER (Side Effect Resource) by MetaLAB and MetaNurse against 11 817 and 76 457 drug-ADR pairs, respectively. Results. We demonstrate that MetaLAB (area under the curve, AUC ¼ 0.61 6 0.18) outperformed CLEAR (AUC ¼ 0.55 6 0.06) when we applied the same 470 drug-event pairs as the gold standard, as in our previous research. Receiver operating characteristic curves for 101 precautionary terms in the Medical Dictionary for Regulatory Activities Preferred Terms were obtained for MetaLAB and MetaNurse (0.69 6 0.11; 0.62 6 0.07), which complemented each other in terms of ADR signal coverage. Novel ADR signals discovered by MetaLAB and MetaNurse were successfully validated against spontaneous reports in the US Food and Drug Administration Adverse Event Reporting System database. Discussion. The present study demonstrates the symbiosis of laboratory test results and nursing statements for ADR signal detection in terms of their system organ class coverage and performance profiles. Conclusion. Systematic discovery and evaluation of the wide spectrum of ADR signals using standard-based observational electronic health record data across many institutions will affect drug development and use, as well as postmarketing surveillance and regulation.
INTRODUCTION
A drug with demonstrated clinical efficacy in many patients can still be ineffective in other patients, or even cause serious side effects, including death. 1, 2 The incidence of severe adverse drug reactions (ADRs) has been estimated at 6.2-6.7% in hospitalized patients, and >2 million ADRs are reported annually in the United States, including 100 000 deaths. 1, 3 It is imperative to be vigilant for ADRs when administering all marketed drugs. 4 The relevance of postmarketing pharmacovigilance has been growing steadily over the last 4 decades. 5, 6 The plethora of prescription, laboratory, and clinical information in electronic health record (EHR) systems has vast potential to drive diverse pharmacovigilance studies. 7, 8 Extracting ADR signals from laboratory results for specific medications has been the primary strategy of EHR-based pharmacovigilance studies, but they have evaluated only small numbers of drugs, ADRs, and their combinations. A comprehensive evaluation of all medications versus all laboratory results and all clinical narratives is still challenging, owing to a lack of efficient analytic algorithms, systematic evaluation strategies, and reliable reference standards for ADR signals.
Nurses reportedly play a more important role in discovering and spontaneously reporting ADRs than doctors and pharmacists. 9, 10 This may be due to nurses' regular clinical observation/recording and more standardized statements compared to the diagnosis codes and test results recorded by doctors. [9] [10] [11] [12] Nursing records contain ADR signals in the form of clinical symptoms and signs, such as dizziness, dry mouth, and weight gain, that are not detectable by laboratory tests. Therefore, combining laboratory results with nursing statements could synergistically extend the usefulness of EHR-based pharmacovigilance. For all nursing documents, the Seoul National University Hospital (SNUH) EHR has applied standard nursing statements (SNSs) encoded by the International Classification for Nursing Practice (ICNP) for 10 years at the institutional level. MetaLAB for laboratory results and MetaNurse for SNSs are significantly improved versions of our previous EHR-based pharmacovigilance algorithm, named CLEAR, 13 powered by an advanced subject-sampling strategy for managing all drugs, all laboratory results, and all SNSs. A meta-analysis technique was applied to correct for yearly variations in drug-prescription and ADR-signal frequency patterns. Furthermore, to enable unbiased and comprehensive validation of ADR signals that are comprehensively detected, 14 we created a comprehensive reference standard for ADR (RS-ADR), integrating and mapping Side Effect Resource 2 (SIDER 2) 15 information and EHR data with standard biomedical vocabularies from the ICNP, International Classification of Diseases (ICD), Logical Observation Identifiers Names and Codes (LOINC), World Health Organization Adverse Reactions Terminology (WHOART), and Medical Dictionary for Regulatory Activities (MedDRA).
METHODS
The ADR signals considered in this study were laboratory test results and SNSs in EHR data. This study was reviewed and approved by the SNUH Institutional Review Board, No. 1211-055-442.
Data sources
We analyzed all EHR data for inpatients obtained from January Figure 1A ).
The 10 reference drugs reported by the CLEAR algorithm 13 were also included so that a fair comparison could be made between the old and new algorithms. We excluded drugs that had redundant ingredients (n ¼ 9), were not used at SNUH (n ¼ 24), had no side effect information in SIDER 2 (http://sideeffects.embl.de/, released on March 16, 2012) (n ¼ 23), and were prescribed to fewer than 100 patients at SNUH (n ¼ 17), which finally yielded 101 study drugs for further investigation. The 101 drugs included in this study are classified according to the Anatomical Therapeutic Chemical (ATC) classification system and mapped to the product name used at SNUH (see Supplementary Table S2) .
Algorithms for ADR signal detection Figure 2 illustrates the 5 steps of inclusion criteria, subject sampling, variable adjustment, signal refinement, and ADR signal detection used in the CLEAR, 13 MetaNurse, and MetaLAB algorithms. The matched-sampling strategy of our previous CLEAR algorithm, 13 involving up-to-1:4 matching for age, gender, admission department, and diagnosis, is prohibitively costly for large-scale applications that involve many drug-ADR pairs due to its computationally intensive and data-demanding nature. MetaLAB and MetaNurse utilized an improved strategy in which comparison groups were created by recruiting all subjects who were not exposed to the study drug, followed by variable adjustments for age, gender, admission department, and disease severity for computing the odds ratio for laboratory results (quantitative measurements) and Cox proportional-hazards ratio for nursing statements (frequency of ADR symptoms). We found that the frequencies of drug prescriptions, laboratory tests, and nursing statements showed slow temporal fluctuations. This was overcome by controlling for yearly variations using the odds and Cox proportional-hazards ratios for each ADR per year from 2005 to 2011 at SNUH in a meta-analysis, which yielded integrated single odds and Cox proportional-hazards ratios, respectively, of that ADR over the study period. Meta-analysis was done using the meta metagen function of the R statistical package (version 4.3-0), using estimate of treatment effect and standard error of treatment estimate for each per year. MetaLAB was applied to the same 47 laboratory abnormalities from 40 laboratory tests used to evaluate CLEAR 13 in a comparison study and also to all 117 laboratory abnormalities from 48 laboratory tests for the present study, to ensure that the evaluation was comprehensive (Figure 2 and Supplementary Table S3) .
CLEAR CLEAR is a replication of our previous implementation for ADR signal detection 13, 23 where ML stands for the MetaLAB algorithm, RS corresponds to the RS-ADR (referring to SIDER 2), and L is a label indicating the laboratory results tested by the 117 laboratory abnormalities.
MetaNurse
MetaNurse is an algorithm applied to SNSs (or frequency of ADR symptoms) instead of laboratory results (or quantitative measurements). MetaNurse determines an ADR signal for a drug when an SNS indicating the ADR is recorded more than twice after the first administration of the drug. Accordingly, we applied a Cox proportional-hazards ratio method by adjusting for age, gender, admitting department, and disease severity. The per-year Cox proportional-hazards ratios for each ADR from 2005 to 2011 at SNUH were input into a meta-analysis to obtain an integrated single Cox proportional-hazards ratio for the ADR over the study period. MetaNurse analysis is denoted as
where MN stands for the MetaNurse algorithm, RS corresponds to the RS-ADR, and N is a label indicating the 1357 SNS terms mapped to 223 WHOART terms. The incidence of an ADR for a drug was defined as the number of patients having the ADR divided by the sum of the durations since the first medication and admission dates for the study and comparison groups, respectively, to the discharge date or date when the third WHOART terms annotated with SNS terms was recorded, whichever occurred earlier.
Reference standard for adverse drug reactions
Given that there is no gold standard available for comprehensively and systematically validating pharmacovigilance studies, we created the RS-ADR by referring to the drug-ADR associations provided by the SIDER 2 database, which uses the MedDRA dictionary to extract ADR information from public documents and package inserts ( Figure associations including SIDER 2 do not provide negative associations, only positive ones. The presence of "no report" or "not found" entries in these resources does not necessarily mean a true-negative association. Moreover, correct evaluations are almost always hampered when there is no gold standard for true negatives. This is one reason why previous studies focused on small numbers of drugs and/or ADRs. In the absence of a true gold standard for drug-ADR associations, we used the SIDER 2 set as the positive reference set for the purpose of current validation. Figure 1B illustrates the steps used to create the RS-ADR by mapping (1) both clinical narratives and ADRs encoded by SNS terms and MedDRA PTs, respectively, to WHOART, (2) SNUH codes for laboratory tests to LOINC, and then LOINC terms and SNUH codes to MedDRA PTs, and (3) administrative classifications for ICD codes to MedDRA PTs. We manually mapped SNS terms (encoded by the ICNP) and MedDRA PTs to WHOART. Presumed drug-ADR associations that do not yet exist in SIDER 2 but are implicitly suggested by this database were explicitly connected as established ADRs. In other words, when a group of MedDRA PTs were mapped to the same WHOART term but only a portion of the PT group was assigned to a drug-ADR association by SIDER 2, all MedDRA PTs in that group were explicitly assigned to the drug as established ADRs. For example, among 5 MedDRA PTs mapped to the same WHOART term (eg, Urticaria, Urticaria chronic, Urticaria physical, Mechanical urticaria, and Urticaria vesiculosa), only Urticaria was reported as an ADR of ranitidine in SIDER 2. We linked the remaining 4 PTs to ranitidine as its ADRs in the RS-ADR (see Supplementary Table S1 ). Filling the gaps between implicit drug-ADR associations using standard ADR terminologies such as WHOART is a critical step when building a reference standard for ADRs; for example, a correct prediction of the ranitidine-Urticaria physical association by a pharmacovigilance algorithm might be evaluated to be incorrect (ie, a false positive). These mapping and manual curation processes for building the RS-ADR in the present study took >2 years and were validated by 3 clinical experts. A detailed description of the RS-ADR will be reported separately.
Of the 3209 MedDRA PTs for 996 drugs in SIDER 2, 1235 Med-DRA PTs were mapped by the RS-ADR to 1439 SNS terms by 239 WHOART PTs for MetaNurse and 191 laboratory abnormalities from 62 laboratory tests for MetaLAB. Of the 1820 MedDRA PTs in 17 740 positive drug-MedDRA-PT pairs for the 101 precautionary drugs in the RS-ADR, 757 MedDRA PTs were mapped to 1357 SNS terms by 223 WHOART PTs for MetaNurse and 117 laboratory abnormalities from 48 laboratory tests for MetaLAB (via LOINC) ( Figures 1C and 2 ).
Evaluation
Logistic regression and Cox proportional-hazards models were applied to calculate the odds ratios and 95% confidence intervals between drug prescriptions and ADR signals indicated by abnormal laboratory results and SNSs, respectively (Figure 2 ). To identify unknown but significant ADRs, we used the 95% confidence interval with a lower limit !1.0 for a drug-adverse event pair as a positive ADR signal, as in our previous study. 13 For calculating AUC (area under the receiver operating characteristic curve [ROC]), we used a meta-regression method widely used in meta-analysis for obtaining ROC curves. 25, 26 The epicalc lroc function of the R statistical package (version 2.15.1.0) creates ROC curves directly from a logistic regression model that are applied to multiple comparisons. We applied adjusted P-values (by the Benjamini-Hochberg method) and binary outcomes (whether the ADRs of the drug were known or not, based on the outcomes listed in SIDER 2) together with odds ratios for MetaLAB or hazard ratios for MetaNurse as input numeric vectors to the epicalc lroc function for evaluating the performance of the 3 algorithms across different MedDRA system organ classes (SOCs) and ATC drug classes (Table 1) . Supplementary Table S5 (a) shows the variables used for calculating an AUC value for the drug atropine as an example. We used the epicalc lroc function in R statistical package to obtain ROC curves. The binary outcome was whether the ADRs of the drug were known or not, based on the outcomes in SIDER2. After obtaining AUC values for each of the 101 drugs against 117 laboratory abnormalities and 1357 SNSs in 757 MedDRA PTs for MetaNurse and MetaLAB, respectively, we (Table 1) .
We also computed AUC values for each of the 101 drugs per each SOC subgroup (Supplementary Table S5 (b)). Because SIDER 2 does not provide negative associations, only positive ones, the nonreported drug-ADR associations are regarded as the referencenegative associations for evaluating massively detected ADR signals. The much bigger negative (than positive) association space of SIDER 2 creates challenging bias, severely overestimating the performance of algorithms that prefer negative calls, and vice versa. By restricting the search space to each SOC, the spurious negative (or nonreported by SIDER 2) drug-ADR associations in the reference set were significantly reduced without affecting SIDER-reported positive associations. Finally, we obtained the SOC-integrated AUC value for each of the 101 drugs by calculating the weighted average and standard deviation of the per-SOC AUC values (Table 1) . These can also be used to compute the overall AUC values for each SOC by calculating the average and standard deviation of the per-SOC AUC values of the 101 drugs (Table 2) . Table 1 and Figure 1 show the clinical characteristics of the study population and precautionary drug inclusion. Patient records were eligible for CLEAR 13 and MetaLAB if the patients had been prescribed at least one target drug at least once and had one or more laboratory result before and after being administered the target drug during the hospitalization period 13 ( Figure 2 ). Patient records were eligible for MetaNurse if the patients had been prescribed at least one target drug at least once and had one or more SNSs in their EHRs (Figure 2 ). (Table 1) . Despite the improved performance of MetaLAB compared to the previous implementation in CLEAR, the ROC values are modest (<0.70). SOC-integrated AUC computation greatly improved the performance of MetaLAB and MetaNurse (0.84 6 0.13 and 0.84 6 0.09, respectively) by separately obtaining an ROC value for each SOC for a drug and then averaging them to obtain the SOC-integrated ROC value for the drug. Otherwise, many SOCs with no signal can hamper the overall performance of an ADR signal detection algorithm, especially when evaluating vastly extended ADR space across all SOCs. Drugs tend to have ADRs enriched in specific SOCs only. For example, phenylephrine's known side effects (n ¼ 4) of laboratory abnormalities are reported only in blood and lymphatic system disorder (n ¼ 2) and investigation (n ¼ 2) SOCs (Supplementary Figure S3) . Figure 3A shows the ROCs by MetaLAB for the same 10 drugs reported by Yoon et al. 13 against the extensive 11 817 drug-ADR pairs in RS-ADR. Despite the vastly extended problem space, MetaLAB showed remarkably improved performance (0.69 6 0.11, Table 1 ). Due to its dependence on a predefined gold standard, 13 CLEAR cannot be tested against all 11 817 drug-ADR pairs but only against the predefined 470 pairs (Table 1) . MetaLAB outperformed CLEAR when evaluated against the same 10 drugs and 47 laboratory abnormalities (ML DE pairs l , 0.61 6 0.18, Table 1 ).
RESULTS

Algorithm performance
System organ class coverage
Standard vocabulary-based mapping enables systematic evaluation of ADR signals across different SOCs and ATC drug classes (Supple mentary Figure S1 ). Six SOCs were covered by both MetaLAB and MetaNurse, but 14 can only be covered by MetaNurse (Table 2) . It should be noted that skin and subcutaneous tissue disorders (AUC ¼ 0.80 6 0.12), nervous system disorders (AUC ¼ 0.67 6 0.12), and psychiatric disorders (AUC ¼ 0.71 6 0.16) are ADRs that are observed very often in clinical settings and are detectible with high prediction accuracy by MetaNurse but not by MetaLAB.
Supplementary Figure S2 shows prediction performance profiles of MetaLAB and MetaNurse. Among 26 MedDRA SOCs, 6 having fewer than 5 MedDRA PTs for MetaNurse were omitted: congenital, familial, and genetic disorders (n ¼ 3); injury, poisoning, and procedural complications (n ¼ 1); neoplasms benign, malignant, and unspecified (n ¼ 3); pregnancy, puerperium, and perinatal conditions (n ¼ 1); social circumstances (n ¼ 1); and surgical and medical procedures (n ¼ 0). * P < .05 by paired t test. AUC data are mean 6 SD values.
As shown in Table 1 Table 1 ). While MetaNurse shows lower overall performance than MetaLAB, much wider ADR domains of MedDRA SOCs are covered by MetaNurse than by MetaLAB ( Table 2 ). The AUC values measured for individual SOCs (Table 2) tend to be bigger than those measured for overall SOCs (Table 1) , simply because a drug-ADR space is defined by the numbers of drugs and ADRs that are counted. The increment by SOC subgroup integration was larger for MetaNurse (0.22), covering more SOCs, than for MetaLAB (0.15) ( Tables 1 and 2 and Supplementary Figure S1 ).
Novel ADR signals
Positively predicted signals for unknown ADRs (or false positives) can be applied for novel ADR discovery. To evaluate false-positive Among 26 MedDRA SOCs, 6 having fewer than 5 MedDRA PTs for MetaNurse were omitted: congenital, familial, and genetic disorders (n = 3); injury, poisoning, and procedural complications (n = 1); neoplasms benign, malignant, and unspecified (n = 3); pregnancy, puerperium, and perinatal conditions (n = 1); social circumstances (n = 1); and surgical and medical procedures (n = 0). *P < .05 by paired t test. AUC data are mean 6 SD values.
ADR signals, spontaneous reports in the FDA Adverse Event Reporting System (FAERS) 27 were annotated with MedDRA and WHOART PTs. Table 3 and Figure 4 exhibit evaluation examples for false-positive signals of 4 exemplar drugs: bisacodyl, prazosin, phenylephrine, and sucralfate. While bisacodyl's ADRs are mainly classified into the Gastrointestinal disorders SOC, 28 MetaNurse detected 25 MedDRA PTs that are unknown but significant in the Cardiac disorders SOC (lower limit of 95% CI ! 1.0) and can be nonredundantly mapped to 6 WHOART PTs, Circulatory failure, ECG abnormality, Hypertension, Hypotension, Cardiac failure, and Cyanosis ( Figure 4A ). Cardiac disorders are not currently known as bisacodyl ADRs, according to Micromedex TM . However, we found that 354 (2.44%) of the 14 645 FAERS reports for bisacodyl 29 were associated with cardiac abnormalities, including 55 congestive heart failure (CHF), 49 atrial fibrillation, and 31 cardiorespiratory arrest reports (Table 3 ). Supplementary Table S4 shows that the baseline or average rate of cardiac abnormalities for all drugs in the FAERS database was 2. 21%, which was lower than bisacodyl's 2.44%. Moreover, docusate sodium and polyethylene glycol 3350, which are known to have side effects involving cardiac abnormalities, showed 2.48% and 1.55%, respectively, and lactulose and senna, which have no known side effects involving cardiac abnormalities, showed 1.93% and 1.95%, respectively. Based on these findings, we concluded that the risk of cardiac abnormalities from bisacodyl is higher than the baseline risk.
Supplementary Figure S4 shows that the statistical significance of the 6 WHOART PTs, circulatory failure, ECG abnormality, hypertension, hypotension, cardiac failure, and cyanosis ( Figure 4A ), were not affected even if we excluded the patients with CHF, for whom laxatives are sometimes prescribed to minimize straining. We performed a detailed analysis of the bisacodyl case by controlling the ICD-10 code for CHF, I-50*. A case with CHF was defined as a patient having a diagnosis code of I-50* before being prescribed bisacodyl. Because only 0.41% had CHF, the overall statistical significance was not affected. CHF was diagnosed in 912 ( ¼ 268 þ 644, 0.41%) but not in 220 042 ( ¼ 45 143 þ 174 692, 99. 59%) patients. Diagnosis of CHF was made before bisacodyl was prescribed according to the analysis steps in our algorithms.
For prazosin, for which known ADRs are gastrointestinal and cardiovascular, 30 
DISCUSSION
MetaLAB and MetaNurse are improved versions of our previous CLEAR algorithm 13 powered by an advanced subject-sampling strategy, a meta-analysis technique that adjusts for yearly variations in drug prescriptions and/or disease prevalence, and a comprehensive reference standard for detecting ADR signals. They assign the records of all patients who are not prescribed the study drug as the comparison group and adjust confounding factors (Figure 2 ). MetaLAB outperformed CLEAR (Table 1) . Most of the previous studies focused on a small number of preselected ADRs such as prolonged QT interval, myocardial infarction, cardiac valve fibrosis, and venous thrombosis. 36, 37 In our previous study 13 where we developed a reference set for the CLEAR algorithm, experts had to manually create and curate a mapping table linking known ADRs and laboratory abnormalities (interobserver agreement j ¼ 0.95; P < .001). For the present study, we created a comprehensive ADR knowledge base, called the RS-ADR, referring automatically to SIDER 2, to be applied to all commercially available drugs and to all nursing statements and laboratory abnormalities. The increasing use of coded nursing statements in EHRs provides an additional opportunity to improve EHR-based pharmacovigilance. The present study demonstrates the symbiosis of laboratory test results and nursing statements for ADR signal detection in terms of their different SOC coverages and performance profiles. Nursing statements contain more standardized and consistent information on dimensions compared to laboratory results. Our use of SNSs makes it possible to detect ADR signals over a wide range of clinical symptoms, such as dermatitis, eyelid ptosis, and sleep disorders. For example, MetaLAB showed high performance for nicardipine (AUC ¼ 0.84), clopidogrel (AUC ¼ 0.69), and lorazepam (AUC ¼ 0.61), whose major ADRs are hypokalemia, leukocytosis, anemia, and abnormal liver function test, which are easily detectible by laboratory tests. In contrast, MetaNurse showed high performance for tolterodine (AUC ¼ 0.79) and mirtazapine (AUC ¼ 0.72), whose major ADRs are diarrhea, anaphylactic shock, and edema, which are more likely to be detected by bedside nursing observations (data not shown).
Pharmacovigilance algorithms can be used to discover novel ADR signals. With improved performance and extended coverage for drugs and ADR signals, we discovered numerous significant ADR signals that had not been identified previously using SIDER 2 and Micromedex TM (Table 3 ). In particular, using clinical observations in nursing statements greatly extended the search space for ADR signals for many SOCs, such as skin and subcutaneous-tissue disorders, nervous system disorders, and psychiatric disorders (Table 2 and Supplemen tary Figure S1 ). Supplementary Figure S2 shows that MetaNurse identifies more novel ADR signals (or false positives) in many SOCs and ATC drug classes than MetaLAB does. Our comprehensive analysis results for all 101 precautionary drugs by MetaNurse and MetaLAB for 22 MedDRA and 7 SOCs are available for further validation by users at our website http://adr.snubi.org/. The present study was subject to some limitations. First, doserelated ADRs were not considered; this would require a database with information on dose-related ADRs, which is not currently available. However, it may be possible to integrate dosing information with our algorithms for a limited number of ADRs whose doserelated effects are well established. Second, the causality between drug exposure and detected ADR signal was not verified. It is necessary to establish causality, since this evaluates the relationship between a drug treatment and the occurrence of an adverse event. 40 Third, comparing the performance of MetaLAB and MetaNurse in ADR signal detection was not straightforward, because there is no established gold standard for validating ADR signal-detection algorithms. We chose to use SIDER 2 as the "silver" standard for performance evaluations. Fourth, some hospitals are not yet using standard nursing statements. However, the results obtained in the present study should encourage the use of coded nursing statements in practice. It is suggested that simple text mining and natural language processing of clinical narratives, including nursing statements, can greatly reduce the incidence of ADRs. Fifth, our subject sampling and matching strategy based on drug exposure vs nonexposure groups could be vulnerable to misinterpretation of drug indications as ADR signals. However, our strategy has the advantage of increasing the study population size, hence compensating for this drug-indication bias to a certain degree, as shown in Supplementary Figure S4 .
